Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial
Frontiers in Immunology · 26.06.2025 · 16
DOI: 10.3389/fimmu.2025.1620366 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Frontiers in Immunology, online erschienen am 26.06.2025. Verfasst von Caroline Bundi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Geographic Medicine Research, Coast, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya. Hauptthemen laut MEDLINE: Malaria Vaccines, Plasmodium falciparum, Malaria, Falciparum, Antibodies, Protozoan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The pre-erythrocytic malaria vaccine R21 vaccine adjuvanted with Matrix-M reported good efficacy (75%) in an ongoing phase 3 trial and was recommended World Health Organization for use in children 5–36 months. Vaccine-induced antibodies against NANP are associated with protection, however, various factors such as age, pre-existing immunity, and vaccine dose have been shown to influence vaccine responses.
Methods
Samples from adults (n =18), children (n = 17), and infants (n = 51) vaccinated with R21/Matrix-M in a phase I trial were assayed for vaccine-specific antibody responses. We measured antibodies (quantity) by MSD and ELISA; and function (quality) by complement (C1q) fixation assay, inhibition of sporozoite invasion (ISI) assay, and avidity assay. Pre-existing malaria antibody exposure was assessed using an anti-3D7 Plasmodium falciparum crude parasite lysate ELISA.
Results
Vaccine-induced CSP antibodies (against full-length R21, NANP, and C terminus), exhibited complement fixation and inhibition of sporozoites. These were significantly lower in adults compared to children and infants. Additionally, children had a higher rate of decay of vaccine-induced antibodies compared to adults 2 years post-vaccination. Furthermore, a higher Matrix-M adjuvant dose resulted in significantly higher C1q fixation, and ISI than the low adjuvant dose in infants. Importantly, functional measures ISI and C1q-fixation were positively associated with the vaccine-induced antibodies overall, but avidity was not. Interestingly, in adults, previous malaria exposure was negatively associated with ISI but positively correlated with avidity and C1q fixation. At baseline, all the study participants were seropositive for anti-HBsAg IgG above the WHO-required protective threshold of 10 mIU/mL, and titers significantly increased post-vaccination.
Discussion
R21/Matrix-M was immunogenic across all age groups, with age and vaccine dose significantly affecting antibody magnitude and function. These findings emphasize the importance of evaluating the right adjuvant and vaccine dose for clinical development progression. This could thus inform the development of next-generation malaria vaccines. However, additional crucial factors need further exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Geographic Medicine Research, Coast, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
- Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania.
- The Jenner Institute, University of Oxford, Oxford, United Kingdom.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University Oxford, Oxford, United Kingdom.
Zitieren
APA
Bundi, C., Bellamy, D., Kibwana, E., Nyamako, L., Ogwang, R., Keter, K., Kimani, D., Salman, A. M., Provstgaard-Morys, S., Stockdale, L., Hill, A. V. S., Bejon, P., Olotu, A., Hamaluba, M., Ewer, K. J., & Kapulu, M. C. (2025). Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1620366
Vancouver
Bundi C, Bellamy D, Kibwana E, Nyamako L, Ogwang R, Keter K, et al. Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1620366
BibTeX
@article{Bundi2025,
author = {Bundi, Caroline and Bellamy, Duncan and Kibwana, Elizabeth and Nyamako, Lydia and Ogwang, Rodney and Keter, Kelvias and Kimani, Domtila and Salman, Ahmed M and Provstgaard-Morys, Samuel and Stockdale, Lisa and Hill, Adrian V S and Bejon, Philip and Olotu, Ally and Hamaluba, Mainga and Ewer, Katie J and Kapulu, Melissa C},
title = {Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial},
journal = {Frontiers in Immunology},
year = {2025},
volume = {16},
doi = {10.3389/fimmu.2025.1620366}
}
EUVIMED